| 1 |
35433455 | Metagenomic Analyses Reveal Distinct Gut Microbiota Signature for Predicting the Neoadjuvant Chemotherapy Responsiveness in Breast Cancer Patients. | 2022 |
1 |
| 2 |
33545713 | A combination of cyclophosphamide and interleukin-2 allows CD4+ T cells converted to Tregs to control scurfy syndrome. | 2021 Apr 29 |
1 |
| 3 |
34329754 | Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation. | 2021 Nov |
1 |
| 4 |
30890769 | Donor-derived CD4+/CCR7+ T-cell impact on acute GVHD incidence following haplo-HCT after reduced intensity conditioning and posttransplant cyclophosphamide. | 2019 Oct |
1 |
| 5 |
30186977 | Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide. | 2018 Aug |
1 |
| 6 |
28132769 | Immunosuppression in sheep induced by cyclophosphamide, bluetongue virus and their combination: Effect on clinical reaction and viremia. | 2017 Mar |
1 |
| 7 |
25655312 | T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses. | 2015 May |
1 |
| 8 |
25950695 | The CD4 Lymphocyte Count is a Better Predictor of Overall Infection Than the Total Lymphocyte Count in ANCA-Associated Vasculitis Under a Corticosteroid and Cyclophosphamide Regimen: A Retrospective Cohort. | 2015 May |
1 |
| 9 |
25251877 | Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis. | 2014 Dec |
3 |
| 10 |
25430593 | Increase of peripheral T regulatory cells during remission induction with cyclophosphamide in active systemic lupus erythematosus. | 2014 Sep |
1 |
| 11 |
23507054 | Infections in vasculitis. | 2013 Feb |
1 |
| 12 |
24376696 | Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: implications for the immune response. | 2013 |
1 |
| 13 |
22285846 | Cyclophosphamide inhibits the generation and function of CD8(+) regulatory T cells. | 2012 Mar |
2 |
| 14 |
22349930 | Changes in immune cell frequencies after cyclophosphamide or mycophenolate mofetil treatments in patients with systemic lupus erythematosus. | 2012 Jun |
1 |
| 15 |
22539294 | Double negative Treg cells promote nonmyeloablative bone marrow chimerism by inducing T-cell clonal deletion and suppressing NK cell function. | 2012 May |
1 |
| 16 |
20857100 | Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia. | 2011 Jan |
1 |
| 17 |
19590872 | Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. | 2010 Jan |
1 |
| 18 |
20139774 | Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. | 2010 Feb-Mar |
1 |
| 19 |
20338811 | CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy. | 2010 Jul |
1 |
| 20 |
20501849 | Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. | 2010 Jun 15 |
2 |
| 21 |
20964639 | Mifepristone (RU486) restores humoral and T cell-mediated immune response in endotoxin immunosuppressed mice. | 2010 Dec |
1 |
| 22 |
21054711 | Therapeutic hotline: Primary cutaneous CD4 + small/medium-sized pleomorphic T cell lymphoma coexisting with myelodysplastic syndrome transforming into chronic myelomonocytic leukemia successfully treated with cyclophosphamide. | 2010 Nov-Dec |
2 |
| 23 |
18199598 | Clinical significance of increased CD4+CD25-Foxp3+ T cells in patients with new-onset systemic lupus erythematosus. | 2008 Jul |
1 |
| 24 |
18443965 | Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma. | 2008 May |
1 |
| 25 |
16960692 | Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. | 2007 May |
1 |
| 26 |
17854912 | High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients. | 2007 Oct |
1 |
| 27 |
17956583 | Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. | 2007 Dec |
1 |
| 28 |
15591121 | Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. | 2005 Apr 1 |
1 |
| 29 |
14698862 | Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis. | 2004 Jan |
2 |
| 30 |
8578886 | [ANCA-associated vasculitis (Wegener's granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis). 3. Therapeutic procedure]. | 1995 Sep-Oct |
1 |
| 31 |
1672870 | Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis. | 1991 May |
2 |
| 32 |
2830969 | Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. | 1988 Mar 15 |
3 |
| 33 |
2950845 | Correlation of clinical and immunologic states in multiple sclerosis. | 1987 Apr |
1 |
| 34 |
2957983 | Cyclophosphamide 'pulses' in chronic progressive multiple sclerosis. A preliminary clinical trial. | 1987 Aug |
1 |
| 35 |
2960008 | Effects of immunosuppressive agents and particularly of cyclophosphamide on lymphocytes subsets in treated multiple sclerosis patients. | 1987 May-Jun |
1 |